Rapamycin (found in Rapa Nui or Easter Island) Beyond Transplant Medicine: Longevity, Mast Cell Activation Syndrome, and Autoimmune Disease Through a Functional Medicine Lens

Yoon Hang "John" Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine

Abstract

Rapamycin (sirolimus), an mTOR inhibitor originally developed for transplant immunosuppression, has emerged as the most extensively studied pharmacologic candidate for mammalian lifespan extension and is now being explored for immune dysregulation conditions relevant to functional and integrative medicine. This review synthesizes current evidence across three domains. In longevity, rapamycin remains the only drug to reproducibly extend lifespan in mice, and the 48-week PEARL trial (2025) demonstrated safety and encouraging signals — particularly lean mass gains and reduced pain in women — at low, intermittent doses in healthy older adults, though no human study has yet shown lifespan extension. In mast cell activation syndrome (MCAS), preclinical data show that mTOR inhibition suppresses mast cell cytokine production, chemotaxis, and survival signaling, and selectively induces apoptosis in D816V-mutated mast cells; however, rapamycin does not inhibit acute FcεRI-mediated degranulation, and no clinical MCAS efficacy data exist. The MCAS application is therefore mechanistically plausible but highly exploratory. In autoimmune disease, rapamycin preferentially expands regulatory T cells (Tregs) while suppressing pathologic effector T cell populations, with the strongest clinical signal in systemic lupus erythematosus (SLE), where Phase 1/2 and observational data demonstrate improved disease activity scores and reduced corticosteroid requirements. Emerging trials in ME/CFS, Long COVID, and Sjögren's syndrome further support mTOR inhibition as a viable immunomodulatory strategy. Ultra-low-dose protocols (1–3 mg once weekly) are discussed for MCAS and immune modulation, where the therapeutic intent is immunomodulation — not immunosuppression — and where integration with lifestyle strategies targeting the same mTOR/AMPK/autophagy axis may offer additive benefit. All off-label applications require individualized dosing, careful monitoring, and transparent communication about the limits of current evidence.

Keywords: rapamycin, sirolimus, mTOR, longevity, mast cell activation syndrome, MCAS, autoimmune disease, regulatory T cells, autophagy, functional medicine, low-dose immunomodulation

Introduction

Rapamycin (sirolimus) is having a second act. Originally isolated from a soil bacterium on Easter Island and FDA-approved as an immunosuppressant for organ transplant recipients, it has become arguably the most talked-about molecule in longevity medicine — and one of the most intriguing prospects for immune dysregulation conditions like mast cell activation syndrome (MCAS) and autoimmune disease.

What makes rapamycin so interesting to those of us practicing functional and integrative medicine isn't just that it extends lifespan in every organism tested so far. It's how it works. By inhibiting the mechanistic target of rapamycin (mTOR) — a master metabolic sensor that governs cell growth, inflammation, autophagy, and immune cell behavior — rapamycin touches nearly every pathway we already care about in functional medicine. And critically, what it does at transplant-level doses and what it does at low, intermittent doses appear to be two very different stories.

This article reviews the current evidence for rapamycin across three domains: healthy aging and longevity, MCAS and mast cell–driven inflammation, and autoimmune disease — with a particular focus on the ultra-low-dose and intermittent protocols most relevant to integrative practice.

Part 1: The Longevity Case — What We Know and What We Don't

The Animal Foundation

Rapamycin remains the only pharmacologic intervention that has reproducibly extended lifespan in mammals across multiple independent laboratories. The National Institute on Aging's Interventions Testing Program (ITP) — the gold standard for rigorous longevity research — demonstrated that rapamycin given to genetically heterogeneous mice starting at 600 days of age (roughly equivalent to 60 human years) extended median lifespan by 9% in males and 14% in females. Follow-up ITP cohorts confirmed this consistently across three independent sites.

Dose-response data further showed that higher dietary rapamycin levels (42 ppm) produced larger lifespan gains — median increases of 23–26% — compared with lower doses (4.7 ppm), though at the cost of more metabolic and immune side effects. Importantly, intermittent parenteral dosing (for example, 4 mg/kg every other day for six weeks in aged mice) also improved survival, suggesting that continuous daily exposure is not required for benefit. This observation has become the rationale underpinning most human longevity protocols.

The PEARL Trial: First Long-Term Human Data

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, published in peer-reviewed form in 2025, represents the longest controlled study of rapamycin use for healthy aging to date. This 48-week, double-blinded, randomized placebo-controlled trial enrolled 114 adults aged 50–85 and evaluated weekly compounded rapamycin at 5 mg or 10 mg against placebo.

Key findings:

• Safety: Adverse event rates were similar across all groups, including placebo. Low-dose, intermittent rapamycin was well tolerated over one year.
• Body composition: The primary endpoint of visceral fat reduction did not reach significance. However, women receiving 10 mg/week demonstrated approximately 6% gains in lean tissue mass from baseline — a meaningful signal for sarcopenia prevention.
• Patient-reported outcomes: Women on 10 mg/week reported less pain. The 5 mg/week group showed improvements in emotional well-being and self-rated health.
• Bioavailability caveat: The compounded rapamycin used in PEARL turned out to be roughly one-third as bioavailable as commercially produced sirolimus. This means the effective doses were approximately 1.7 mg and 3.3 mg/week in pharmaceutical-grade equivalents — placing them well below most clinical protocols.

This bioavailability finding is clinically important. Clinicians prescribing compounded formulations and those using commercial/generic sirolimus are not working with the same drug potency, milligram for milligram. The PEARL investigators' comparative bioavailability data used commercial generic tablets, not specifically branded Rapamune®, so the 1.7 and 3.3 mg figures should be understood as approximate commercial-formulation equivalents rather than precise pharmacologic equivalencies.

Other Human Signals

Before PEARL, the most widely cited human data came from Mannick et al., who showed that healthy elderly individuals taking a low-dose rapalog (0.5 mg daily or 5 mg/week for six weeks) demonstrated improved immune responses to influenza vaccination and reduced markers of immune aging (PD-1+ T cells). This was a short study, but it made a crucial conceptual point: at low, intermittent doses, mTOR inhibition can enhance certain aspects of immune function — the opposite of what transplant-dose rapamycin does.

A 2025 review from George Washington University offered a candid assessment: the data in humans have yet to establish that rapamycin is a proven senotherapeutic that can delay aging in healthy older adults. The absence of well-funded industry trials — rapamycin is generic, so there is no commercial incentive for large Phase 3 work — means high-quality evidence will likely come slowly.

What Rapamycin Does at the Cellular Level

For functional medicine practitioners, it helps to understand the downstream mechanisms:

• Autophagy activation: mTORC1 inhibition releases the brake on autophagy — the cellular housekeeping process that clears damaged proteins, dysfunctional mitochondria, and senescent cell debris. This is the same pathway activated by fasting, caloric restriction, and exercise.
• Senescent cell suppression: Rapamycin suppresses the senescence-associated secretory phenotype (SASP) — the cocktail of inflammatory cytokines, chemokines, and proteases that senescent cells pump out to damage surrounding tissue. This appears to occur through both Nrf2-dependent and Nrf2-independent mechanisms.
• mTORC1 selectivity: Intermittent dosing preferentially inhibits mTORC1 while allowing mTORC2 — which supports immune function, insulin signaling, and cell survival — to recover between doses. This distinction is clinically critical. Continuous high-dose rapamycin inhibits both complexes and produces the immunosuppression and metabolic side effects seen in transplant medicine.

Part 2: Rapamycin, Mast Cells, and MCAS — An Underexplored Frontier

The mTOR-Mast Cell Connection

For those of us who treat MCAS — and I've written extensively about this in MCAS: Epidemic in Plain Sight — the mTOR pathway is not an unfamiliar player. What many clinicians don't realize is how directly mTORC1 controls mast cell behavior.

The mTORC1 pathway is critical for mast cell activation and function. Stimulation of the high-affinity IgE receptor (FcεRI) or the KIT receptor activates the PI3K/Akt/mTOR cascade, and rapamycin modulates several — but not all — downstream mast cell responses. The preclinical picture is more nuanced than it might first appear:

• Cytokine and chemotaxis inhibition (but not degranulation): In a key experimental study, Kim et al. found that rapamycin completely blocked FcεRI- and KIT-induced phosphorylation of p70S6K and partially blocked 4E-BP1 phosphorylation. However, rapamycin did not inhibit acute FcεRI-mediated mast cell degranulation. What it did suppress was cytokine production, KIT-mediated chemotaxis, and mast cell survival. This is an important distinction: rapamycin appears to modulate mast cell inflammatory signaling and survival without directly preventing the acute release of preformed mediators like histamine.
• Complexity of the mTOR-degranulation relationship: Adding further nuance, Rakhmanova et al. demonstrated that experimentally activating mTORC1 (using the mTOR agonist MHY1485) actually suppressed FcεRI-mediated degranulation and cytokine secretion. This counterintuitive finding suggests that the relationship between mTOR signaling and mast cell degranulation is bidirectional and context-dependent — not a simple on/off switch.
• D816V mutation sensitivity: In systemic mastocytosis, the D816V KIT mutation constitutively activates the mTOR pathway. Gabillot-Carré et al. demonstrated that rapamycin specifically induces apoptosis in mast cells bearing this mutation while leaving normal mast cells unaffected — a selectivity that even imatinib does not share for this particular mutation.
• Dual PI3K/mTOR inhibition: Blatt et al. showed that NVP-BEZ235 (a dual PI3K/mTOR blocker) exerted profound inhibitory effects on growth and IgE-dependent activation of both normal and neoplastic mast cells and basophils, suggesting that the mTOR node remains a meaningful therapeutic target for mast cell–driven disease — even if mTOR's role in degranulation per se is complex.

Why This Matters for MCAS

MCAS is fundamentally a disease of aberrant mast cell activation — not proliferation (which distinguishes it from mastocytosis). The mast cells are morphologically normal but functionally hyperreactive, degranulating in response to triggers that should not provoke a response.

Current MCAS treatment relies on layered antimediator therapy: H1 and H2 receptor antagonists, mast cell stabilizers (cromolyn, ketotifen), leukotriene receptor antagonists, and occasionally omalizumab. These approaches block the downstream effects of degranulation but do nothing to address the upstream signal dysregulation driving the hyperactivation.

This is where rapamycin becomes conceptually interesting — though the rationale requires honest framing. The preclinical data do not show that rapamycin directly prevents mast cell degranulation. What they do show is that mTOR inhibition reduces mast cell cytokine production, chemotaxis, and survival — and in the specific context of the D816V mutation, induces selective apoptosis. In MCAS, where the pathology extends well beyond histamine release to include a broad inflammatory mediator profile (prostaglandins, leukotrienes, cytokines, chemokines), targeting the cytokine and survival arms of mast cell signaling could still be clinically meaningful. The hypothesis is not that rapamycin prevents degranulation, but that it may reduce the overall inflammatory output and hyperreactivity of a dysregulated mast cell population. This remains a hypothesis, not an established mechanism.

The Ultra-Low-Dose Hypothesis: 1 mg Per Week

No published trial has yet tested rapamycin specifically in MCAS. But the mechanistic rationale — combined with the emerging safety profile of ultra-low-dose protocols — makes this a reasonable area for clinical exploration.

At 1 mg per week of commercial rapamycin, we are operating well below the doses used in transplant medicine (typically 2–5 mg daily) and even below the PEARL trial's effective range. At this dose, the pharmacological intent is not immunosuppression. It is gentle, intermittent mTORC1 modulation — enough to nudge autophagy, dampen SASP, and potentially reduce mast cell inflammatory cytokine output and survival signaling without meaningfully impairing immune surveillance. Whether this translates to symptom improvement in MCAS is unknown — no clinical data exist — but the theoretical basis and the favorable safety profile at this dose make it a reasonable area for careful clinical exploration.

This approach aligns with a principle familiar to functional medicine: the therapeutic window for immune modulation is often narrower and lower than the therapeutic window for immune suppression. We are not trying to shut down the immune system. We are trying to recalibrate it.

Practical Considerations for MCAS Patients

MCAS patients are, by definition, reactive. Any new medication — even one with a favorable safety profile at low doses — can itself become a trigger. Practical considerations include:

• Excipient sensitivity: Compounded rapamycin may contain fillers or binders that trigger mast cell reactivity. Commercial Rapamune® tablets contain lactose monohydrate, sucrose, and other inactive ingredients that some MCAS patients do not tolerate. Compounding pharmacies can prepare rapamycin in minimal-excipient formulations, though bioavailability will differ (as the PEARL data highlighted).
• Start extremely low: In a population that reacts to everything, a starting dose of 0.5–1 mg once weekly, with careful symptom tracking for 4–6 weeks before any escalation, is prudent.
• Monitor for paradoxical flares: mTOR inhibition can transiently increase autophagy-mediated cellular turnover, which may temporarily increase inflammatory signaling before the net effect becomes anti-inflammatory. Patients should be counseled about this possibility.
• Combination with existing MCAS therapy: Rapamycin would be used as an adjunct — not a replacement — for H1/H2 blockers, cromolyn, and other stabilizers. The goal is additive upstream modulation.

Part 3: Rapamycin and Autoimmune Disease — Tregs, Tolerance, and the mTOR Axis

The Treg Connection

One of rapamycin's most elegant immunologic effects is its differential impact on T cell subsets. While conventional immunosuppressants tend to broadly suppress immune function, rapamycin preferentially inhibits effector T cells (Th1, Th17, and CD4−CD8− double-negative T cells) while promoting the expansion and function of CD4+CD25+FoxP3+ regulatory T cells (Tregs).

This is not a subtle effect. Multiple studies have demonstrated that rapamycin:

• Inhibits the proliferation and function of CD25− conventional effector T cells while permitting the preferential expansion of Tregs.
• Increases circulating Treg numbers and enhances their suppressive capacity in vivo.
• When combined with low-dose IL-2, produces synergistic Treg expansion with suppression of effector T cell proliferation.

For autoimmune disease — where the core pathology is a failure of immune tolerance and an imbalance between effector and regulatory T cell populations — this selectivity is precisely what you want.

Clinical Evidence in Autoimmune Conditions

Systemic Lupus Erythematosus (SLE): The most robust clinical data for rapamycin in autoimmunity comes from SLE. A Phase 1/2 open-label trial at SUNY Upstate (Lai et al., Lancet, 2018) enrolled 43 patients with active SLE resistant or intolerant to conventional medications. Sirolimus at 1–3 mg/day produced progressive improvement in disease activity scores, particularly mucocutaneous and musculoskeletal manifestations. A Swedish group has reported more than 16 years of experience with sirolimus for non-renal SLE manifestations, with similar findings. A meta-analysis of nine studies (145 patients, 245.8 patient-years of exposure) confirmed significant decreases in SLEDAI scores, BILAG scores, and prednisone requirements.

The mechanistic basis is compelling: mTOR is abnormally activated in SLE T cells, driving the expansion of pro-inflammatory T cell subsets and suppressing Tregs. Rapamycin directly corrects this imbalance.

ME/CFS and Long COVID: Two distinct research programs are advancing rapamycin in infection-associated chronic illness. The Simmaron Research observational trial (NCT06257420) enrolled 86 ME/CFS patients on low-dose rapamycin (up to 6 mg/week). The peer-reviewed results, published in the Journal of Translational Medicine in 2025 (Ruan et al.), reported that 52 of the 70 patients who completed at least the first follow-up (74.3%) showed improvement in fatigue, post-exertional malaise, and orthostatic intolerance, with corresponding improvements in autophagy markers (decreased phospho-Ser258-ATG13, increased BECLIN-1). These results are uncontrolled and should be interpreted with caution, but they are mechanistically coherent.

Separately, a randomized, placebo-controlled Long COVID trial (NCT06960928), sponsored by the Icahn School of Medicine at Mount Sinai in collaboration with PolyBio Research Foundation, is currently recruiting. This study uses weekly dose escalation (1 mg → 2 mg → 4 mg) and will provide the controlled data this field needs.

Sjögren's Syndrome: A completed randomized Phase 1/2 study (NCT05605665) evaluated rapamycin alone, low-dose IL-2 alone, and their combination in 30 patients with Sjögren's syndrome. Results have not yet been posted on ClinicalTrials.gov, but the trial's completion reflects the growing clinical interest in mTOR inhibition for autoimmune conditions characterized by Treg insufficiency.

Broader Preclinical Support: In rodent models, sirolimus has demonstrated efficacy in suppressing immune-mediated events associated with collagen-induced arthritis, autoimmune type 1 diabetes, autoimmune myocarditis, experimental allergic encephalomyelitis, graft-versus-host disease, and autoimmune uveoretinitis — essentially the full spectrum of autoimmune pathology.

The Functional Medicine Frame

What makes rapamycin conceptually appealing from a functional medicine perspective is that it targets immune dysregulation rather than immune suppression. The distinction matters.

Conventional immunosuppressants (methotrexate, azathioprine, mycophenolate, biologics) generally work by reducing overall immune activity. This controls disease but comes at the cost of infection risk, malignancy risk, and the ongoing suppression of immune surveillance.

Low-dose rapamycin, by contrast, appears to rebalance the immune system — promoting Tregs, suppressing pathologic effector populations, enhancing autophagy, and reducing the inflammatory secretome of senescent cells — without globally suppressing immune function. At longevity-range doses, some data suggest it may actually improve certain immune parameters.

This is, in essence, immunomodulation rather than immunosuppression — a distinction that resonates deeply with the functional medicine philosophy of restoring physiologic balance rather than overriding it.

Part 4: Practical Dosing Frameworks for Integrative Practice

The following are not prescriptive recommendations. They reflect how clinicians and researchers are currently approaching off-label rapamycin use across these three domains, and should be considered only in the context of individualized clinical decision-making.

Longevity Protocol

• Starting dose: 2–3 mg commercial rapamycin (or bioavailability-equivalent compounded dose) once weekly for 4–6 weeks.
• Titration: If well tolerated, increase by 1–2 mg increments to a typical range of 5–10 mg once weekly.
• Schedule: Weekly dosing is preferred. Some protocols incorporate cycling (6 weeks on, 2 weeks off) or extend intervals to every 10–14 days.
• Administration: Take with a consistent meal containing some fat. Avoid grapefruit, Seville oranges, and pomelo (CYP3A4/P-gp interactions).

MCAS / Immune Modulation Protocol (Exploratory)

• Starting dose: 0.5–1 mg commercial rapamycin once weekly.
• Observation period: 4–6 weeks minimum before any dose adjustment.
• Escalation: If tolerated without flare, consider increasing to 1–2 mg once weekly. Most functional medicine clinicians working in this space stay at 1–3 mg weekly for MCAS.
• Combination: Continue all existing antimediator therapy. Rapamycin is additive, not replacement.
• Excipient awareness: Use minimal-excipient compounding if commercial formulations trigger reactivity, with awareness of bioavailability differences.

Autoimmune Protocol

• Dose range: Published data in SLE used 1–3 mg daily (much higher total weekly exposure than longevity protocols). Weekly intermittent dosing for autoimmune modulation is not well studied but is being explored.
• Consider Treg-promoting adjuncts: Low-dose IL-2, vitamin D optimization, omega-3 fatty acids, and gut microbiome restoration all independently support Treg function and may act synergistically.
• Disease-specific monitoring: Standard autoimmune disease activity indices plus Treg quantification (CD4+CD25+FoxP3+ flow cytometry) if available.

Monitoring Across All Indications

• Baseline labs: CBC with differential, CMP, fasting glucose, HbA1c, lipid panel, liver enzymes.
• During titration: Repeat every 6–12 weeks.
• Once stable: Every 3–6 months.
• Hold or reduce dose for: Recurrent infections, significant lipid or glucose elevations, mouth ulcers/stomatitis, mucocutaneous toxicity, GI intolerance.
• Contraindications/cautions: Pregnancy, breastfeeding, active infection, significant immunosuppression, uncontrolled diabetes, certain cardiovascular conditions.

Part 5: Integrating Rapamycin with Lifestyle and Functional Medicine Strategies

Rapamycin does not operate in a vacuum. The same mTOR/AMPK/autophagy axis it modulates is also influenced by lifestyle interventions that functional medicine practitioners already leverage:

• Resistance training activates AMPK and promotes autophagy in skeletal muscle, complementing rapamycin's effects on lean mass preservation. Timing protein intake around training sessions can optimize mTOR activation in muscle while maintaining systemic mTOR inhibition.
• Time-restricted eating and periodic fasting amplify autophagy beyond what rapamycin achieves alone. Some practitioners recommend taking rapamycin on fasting days to potentiate the autophagy signal.
• Sleep optimization is a potent modulator of cellular repair processes, including autophagy and glymphatic clearance.
• Metabolic health optimization (insulin sensitivity, glucose variability management, lipid optimization) addresses the metabolic risks that rapamycin can exacerbate at higher doses, making it safer to use at any dose.
• Microbiome support is particularly relevant for MCAS patients, where gut-mast cell crosstalk is a known driver of symptom flares. Restoring microbial diversity may reduce the antigenic burden that triggers mast cell activation, potentially complementing rapamycin's effects on mast cell inflammatory signaling.

Conclusion

Rapamycin sits at an unusual crossroads in medicine. It has the strongest preclinical longevity data of any known compound, genuine mechanistic logic for immune dysregulation conditions like MCAS, and growing clinical evidence in autoimmune disease — yet it remains under-prescribed, under-studied, and poorly understood outside of transplant medicine.

For functional and integrative medicine practitioners, the appeal is not that rapamycin is a magic bullet. It is that mTOR inhibition represents a leverage point — a node in the network of inflammation, immune tolerance, autophagy, and metabolic signaling where a well-placed, well-dosed intervention can shift the system toward balance rather than simply suppressing symptoms.

The evidence is still early. No study has demonstrated lifespan extension in humans. No trial has tested rapamycin in MCAS. The autoimmune data, while encouraging, come from small studies of heterogeneous design. But the mechanistic coherence is strong, the safety profile at low doses is reassuring, and the clinical need — particularly for MCAS and autoimmune patients who have exhausted conventional options — is real.

As with all off-label use, the standard applies: start low, go slow, monitor carefully, and let the patient's response guide the next step. In a field built on individualized, root-cause-oriented medicine, rapamycin deserves a place in the conversation.

Summary of Key Takeaways

For Longevity: Rapamycin is the only pharmacologic agent to reproducibly extend mammalian lifespan. The PEARL trial confirms that low-dose, intermittent rapamycin (approximate commercial equivalents of 1.7–3.3 mg/week) is safe over 48 weeks in healthy adults aged 50–85. Secondary signals — lean mass preservation and reduced pain in women — are encouraging but subgroup-driven. No human study has demonstrated lifespan extension. The most commonly used longevity protocol is 5–10 mg of commercial/generic sirolimus once weekly. Compounded rapamycin is roughly one-third as bioavailable as commercial formulations — a critical consideration for clinicians and patients.

For MCAS: The mTOR pathway is directly involved in mast cell cytokine production, chemotaxis, and survival, and rapamycin modulates these functions preclinically. However, rapamycin does not inhibit acute FcεRI-mediated mast cell degranulation, and the relationship between mTOR signaling and degranulation is bidirectional and context-dependent. No clinical trial has tested rapamycin in MCAS. The application is mechanistically plausible but entirely exploratory. Ultra-low-dose protocols (0.5–1 mg commercial rapamycin once weekly) may offer a favorable risk-benefit ratio for cautious clinical exploration in refractory MCAS patients, used as an adjunct to standard antimediator therapy — not a replacement.

For Autoimmune Disease: Rapamycin preferentially expands Tregs and suppresses pro-inflammatory effector T cell subsets — a fundamentally different mechanism from conventional immunosuppression. The strongest human data are in SLE (Phase 1/2 trial, meta-analysis of 9 studies, >16 years of institutional experience), with consistent improvements in disease activity and corticosteroid reduction. Early-stage trials in ME/CFS, Long COVID, and Sjögren's syndrome are active or recently completed. The autoimmune use case is further along than the MCAS use case but still rests on small, heterogeneous studies.

For Integrative Practice: Rapamycin targets the same mTOR/AMPK/autophagy axis already modulated by fasting, resistance training, sleep optimization, and metabolic health interventions. Used at low, intermittent doses, it functions as an immunomodulator — not an immunosuppressant. Pairing rapamycin with these lifestyle levers is a rational, lower-risk strategy. Monitoring (CBC, CMP, fasting glucose, HbA1c, lipids) should occur every 6–12 weeks during titration and every 3–6 months once stable. All applications are off-label and require individualized clinical judgment.

What We Still Don't Know: No human lifespan data exist. No MCAS trial exists. Optimal dose, schedule, and duration for each indication are undefined. The bioavailability gap between compounded and commercial formulations complicates dose comparisons across studies and clinical practice. Larger, longer, controlled trials — ideally using pharmaceutical-grade sirolimus — are needed before any of these applications can move from "promising hypothesis" to "established therapy."

Disclosures: The author has no financial relationships with pharmaceutical manufacturers of rapamycin/sirolimus. This article reflects off-label clinical reasoning based on published data and clinical experience, and should not be construed as medical advice for any individual patient.

Suggested citation: Kim YH. Rapamycin beyond transplant medicine: Longevity, mast cell activation syndrome, and autoimmune disease through a functional medicine lens. IFM Synergy Blog. 2026.

References

1. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. doi:10.1038/nature08221.
2. Miller RA, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13(3):468-477.
3. Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025;17(4):908-936. doi:10.18632/aging.206235.
4. Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
5. Chen C, Liu Y, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009;2(98):ra75. doi:10.1126/scisignal.2000559.
6. Gabillot-Carré M, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood. 2006;108(3):1065-1072. doi:10.1182/blood-2005-06-2433.
7. Kim MS, et al. Activation and function of the mTORC1 pathway in mast cells. J Immunol. 2008;180(7):4586-4595.
8. Blatt K, et al. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One. 2012;7(1):e29925. doi:10.1371/journal.pone.0029925.
9. Rakhmanova V, Jin M, Shin J. Inhibition of mast cell function and proliferation by mTOR activator MHY1485. Immune Netw. 2018;18(3):e18.
10. Lai ZW, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018;391(10126):1186-1196. doi:10.1016/S0140-6736(18)30485-9.
11. Eriksson P, et al. Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus. Front Pharmacol. 2019;10:82.
12. Ji L, Xie W, Zhang Z. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(5):1073-1080.
13. Peng L, et al. Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20953336.
14. Hester J, Schiopu A, Nadig SN, Wood KJ. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant. 2012;12(8):2008-2016. doi:10.1111/j.1600-6143.2012.04065.x.
15. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105(12):4743-4748.
16. Arriola Apelo SI, et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell. 2016;15(1):28-38.
17. Ruan Y, et al. Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy. J Transl Med. 2025. doi:10.1186/s12967-025-07213-8.
18. Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions. NCT06257420. ClinicalTrials.gov. Sponsor: Simmaron Research.
19. Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19. NCT06960928. ClinicalTrials.gov. Sponsor: Icahn School of Medicine at Mount Sinai / PolyBio Research Foundation.
20. Low-dose Interleukin-2 and Rapamycin on Sjögren's Syndrome. NCT05605665. ClinicalTrials.gov. Status: Completed.
21. Wang R, et al. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism. Aging Cell. 2017;16(3):564-574. doi:10.1111/acel.12587.
22. Wang R, Sunchu B, Perez VI. Rapamycin and the inhibition of the secretory phenotype. Exp Gerontol. 2017;94:89-92. doi:10.1016/j.exger.2017.01.026.
23. Hands JM, Lustgarten MS, Frame LA, Rosen B. What is the clinical evidence to support off-label rapamycin therapy in healthy adults? Aging (Albany NY). 2025;17(8):2079-2088. doi:10.18632/aging.206300.
24. Sirolimus (Rapamune®) prescribing information. DailyMed, U.S. National Library of Medicine. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a71c205f-7acc-40e5-9eee-69daeb49a352.